Pfizer introduces its next-gen 20-valent pneumococcal conjugate vaccine (PCV20) in India for adult immunization against 20 ...

Single-dose PCV20 approved for adults 18 years and older, covering 20 pneumococcal serotypes, including both invasive and non ...

Pfizer's share price gained today after the company announced the launch of its next-generation 20-valent pneumococcal ...

PCV20 will be available as a single-shot vaccine and those vaccinated with PCV20 may not need a second dose, the drug maker ...

Pfizer has introduced its 20-valent pneumococcal conjugate vaccine, PCV20, in India to provide protection against 20 serotypes of pneumococcal disease. The single-shot vaccine is aimed at adults, ...

Stocks like Highway Infrastructure, Hindalco Industries, Pfizer, Medi Assist, Adani Enterprises, and HG Infra Engineering ...

Pfizer Malaysia announced that its 20-valent pneumococcal conjugate vaccine (PCV20) has been approved by the Ministry of ...

Indian benchmarks indices, the BSE Sensex and NSE Nifty, are set to open in positive terrain on Tuesday, taking firm cues ...

Key inflation data and earnings from major companies such as HAL, ONGC, and Suzlon are expected to set the near-term tone.

The Korea Disease Control and Prevention Agency announced on 4th that it plans to implement free vaccinations for the 20-valent pneumococcal conjugate vaccine (PCV20) starting from Oct. 1. The target ...

“PCV20 offers broader protection and simplifies the process to a single dose, making it more convenient for patients and doctors alike.” In Malaysia, vaccine uptake among adults remains low.